Skip to main content
Premium Trial:

Request an Annual Quote

Beyond Genomics Changes Name to BG Medicine, Pursues Drug-Development Applications

NEW YORK, Feb. 4 (GenomeWeb News) - Shifting its focus, Beyond Genomics has changed its name to BG Medicine and will now pursue the drug-development applications of its systems pharmacology platform, the company said yesterday.


As part of the realignment, the company appointed Pieter Muntendam as its new president, the statement said. Muntendam most recently led the Biopharmaceutical and Healthcare division of NetNumina, an informatics services company, the statement added.


According to BG, its systems pharmacology platform integrates metabolite, protein, and gene transcript profiling to "characterize the molecular changes due to disease or drug effects." The company's goal will be to "improve upon leading drug classes, identify new indications, and explore novel drug combinations," Muntendam said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.